Sergio Quezada
Founder bij ACHILLES THERAPEUTICS PLC
Vermogen: 466 571 $ op 31-03-2024
Profiel
Sergio Quezada is the founder of Achilles Therapeutics UK Ltd.
(founded in 2016) and Achilles Therapeutics Plc (founded in 2020), where he holds the title of Chief Scientific Officer.
He is currently a Professor-Cancer Institute at University College London since 2011.
Dr. Quezada obtained his undergraduate degree from Pontificia Universidad Católica de Chile and his doctorate from Dartmouth Medical School.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 01-02-2023 | 373 257 ( 0.92% ) | 466 571 $ | 31-03-2024 |
Actieve functies van Sergio Quezada
| Bedrijven | Functie | Begin |
|---|---|---|
| ACHILLES THERAPEUTICS PLC | Founder | 01-11-2020 |
| University College London | Corporate Officer/Principal | 01-01-2011 |
Eerdere bekende functies van Sergio Quezada
| Bedrijven | Functie | Einde |
|---|---|---|
Achilles Therapeutics UK Ltd.
 Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | Founder | - |
Opleiding van Sergio Quezada
| Pontificia Universidad Católica de Chile | Undergraduate Degree |
| Dartmouth Medical School | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| ACHILLES THERAPEUTICS PLC | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Achilles Therapeutics UK Ltd.
Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | Health Technology |
